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1. Introduction 
The extravasation of leukocytes from the vasculature to the tissue space is a fundamental 
response of the normal immune system. A multistep model of leukocyte adhesion to 
vascular endothelium has been characterized, although details of the signaling differ 
between tissues 1-9.  
Lymphocytes recirculate between blood and tissues as part of the immune surveillance 
process, and recent evidence suggests that specialized subsets of T cells exhibit discrete 
tissue-specific patterns of recirculation in vivo 2, 10.  
These cells are directed to particular tissues by combinations of adhesion molecules and 
chemokines that control the lymphocyte recognition of and adhesion to endothelium. For 
example, memory T cells that recirculate to the gut lamina propria express integrin ┙4┚7 and 
bind to an endothelial ligand, namely, mucosal cell adhesion molecule-1, which is detected 
in gut endothelium 11. Conversely, T cells that migrate to the skin do not express ┙4┚7 but do 
express high levels of the lymphocyte Ag, Which binds to E-selectin on dermal endothelium 
12 .The liver is a major site of Ag exposure and contains large numbers of lymphocytes even 
under normal conditions. These lymphocytes are differentiated lymphocytes that are 
displaced by apoptosis 13-17. It is thus likely that tissue-specific signals regulate lymphocyte 
recruitment to the liver 18.  
The hepatic cells are formed into ranks by specialized endothelium that supports 
lymphocyte adhesion and recruitment in a low-shear environment 19. Hepatic endothelium 
has a discrete phenotype compared with endothelium from other vascular beds.  
Several cell adhesion molecules play an important role in this complex process and stabilize 
the adhesion and diapedesis of leukocytes across the endothelial barrier, similar to the 
manner in which human hepatic endothelium cells secrete the endothelial adhesion 
molecule vascular adhesion protein-1 (VAP-1)-9.  
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The VAP-1 molecule is a 170 kDa homodimeric glycoprotein that consists of two 90 kDa 
subunits that are held together by disulfide bonds 20. VAP-1 has a large extracellular 
domain, a single-pass transmembrane domain, and a short cytoplasmic cue 21. The molecule 
has ample sialic acid moieties that are required for its adhesive function, which was shown 
based on the inability of VAP-1 to mediate lymphocyte adhesion to desialylated vessels 20 . 
The leukocyte ligand for VAP-1 is presently unknown. 
Serum measurements of VAP-1 are performed by enzyme-linked immunosorbent assay22.  
A possible role for VAP-1 was shown in adhesion assays. VAP-1 may have a normal 
physiological role in maintaining the proadhesive status of PBLs toward endothelia since its 
concentration in normal individuals is within the range that is used in these adhesion 
experiments.  
Some reports have shown that significantly elevated levels of VAP-1 were found in patients 
with liver diseases 22, 23. Patients had increased systemic circulation, and VAP-1 levels in 
these patients were higher, suggesting that VAP-1 could engender biological effects. It is 
interesting that patients with hepatocellular carcinoma had higher VAP-1 values than 
patients with inflammatory liver diseases, which agrees well with the finding of high VAP-1 
expression in primary liver tumors but not in liver metastases 22-24. Other non-hepatic 
inflammatory diseases were not related to increased levels of VAP-1 23. An increase in VAP-
1 levels is specific to particular inflammatory diseases. The specificity of increased VAP-1 
levels for certain liver diseases (hepatocellular carcinoma) justifies further characterization 
of the role of VAP-1 in the inflammatory activity of these diseases. 
In conclusion, VAP-1 is present in the serum of healthy individuals at a level similar to those 
of most other soluble endothelial adhesion molecules 25. The concentration of VAP-1 is 
higher in certain liver diseases than the levels of other known circulating endothelial 
adhesion molecules 23, 25.   
2. Vascular adhesion protein-1 and hepatocellular cancer 
Unmixed lymphocytes travel continuously throughout the body in search of antigens. 
Blood-borne lymphocytes leave the circulation by binding to the endothelium of specialized 
postcapillary high endothelial venules (HEVs) in lymph nodes, move through the tissue 
stroma, and later return to the circulation via efferent lypmhatics 26. Elemental lymphocytes 
can freely circulate through both peripheral lymph nodes (PLNs) and mucosa-associated 
lymphatic tissues, which represent two functionally different re-circulatory systems. It has 
been known for some time that T cells immigrate and bind to PLN 2-5 times more frequently 
than B cells. On the contrary, B cells adhere 2-3 times more frequently than T cells to HEVs 
in mucosal lymphatic organs. When unmixed lymphocytes adhere to their related antigens, 
the migratory properties of the activated lymphocytes change dramatically. They no longer 
freely circulate through different lymphatic organs but instead selectively extravasate at 
sites of the original antigenic and in related lymphoid tissues 27.         
Lymphocyte exchange between the circulation and tissues is essential for the appropriate 
function of the immune system. In the extravasation function, blood-borne cells make 
primary contacts with endothelial adhesion molecules, which may stimulate grappling, 
activation, entrenched binding, and finally transmigration 1, 27. The grappling cells can be 
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exposed to activating stimuli such as chemokines that can reinforce the integrin-dependent 
adhesion of leukocytes and migration through vessel walls using adhesion molecules from 
immunoglobulin and other super-families as well as local protease activity. Immune 
function is predicated on the continuous exchange of lymphocytes between the blood and 
tissue and is regulated by molecular interactions between the circulating lymphocytes and 
ligands on the surface of endothelial cells 28.  
VAP-1 was described after monoclonal antibody (mAB) 1B2 immunoprecipitation, which 
gave a 170- to 180-kDa homodimeric sialoglycoprotein that was formed by two 90 kDa 
subunits, bound by disulfide bonds, with close sequence homology to the copper-dependent 
semicarbazide-sensitive amine oxidases (SSAO) 1, 20. Both the transmembrane and soluble 
forms of VAP-1 exhibit monoamine oxidase activity 29. A rabbit homolog of VAP-1 has been 
shown to function under in vivo conditions during the primary temporary interactions 
between endothelial and lymphoid cells 20. VAP-1 has a large extracellular domain, a single-
pass transmembrane domain, and a short cytoplasmic cauda 20.  
Soluble adhesion molecules may have definite and adverse physiological effects. They may 
function as inhibitors of cell to cell adhesion by competing with their membrane-bound 
forms.            
Serum measurements of VAP-1 were performed by enzyme-linked immunosorbent assay 
(ELISA). Blood was drawn into serum tubes and allowed to clot for at least 30 min, 
centrifuged at 3000 rpm for 10 min and kept frozen at -70°C 22. Wells of microtiter plates 
were coated with 100 µl of the anti–VAP-1 mAb TK8-18 at 10 µg/ml in 0.1 M NaHCO3 
buffer (pH 9.6), stored at 40Covernight, and then kept at 37°C for 1 h. The wells were 
washed 6 times with 0.1% Tween 20 in phosphate buffered saline (PBS) and then blocked by 
the addition of 200 µl of PBS containing 1% gelatin and 1% nonfat milk powder (blocking 
solution) for 45 min at room temperature to prevent nonspecific adsorption. After washing 
the wells 6 times with Tween/PBS, 175 µl of each serum sample was added to the wells, and 
the plates were left at room temperature for 1 h. The wells were then washed six times with 
Tween/PBS and incubated with 100 µl of the biotinylated anti–VAP-1 mAbTK8-14 or 
biotinylated control mAb Hermes-3 at room temperature for 1 h. After six washes with 
Tween/PBS, 100 µl of streptavidin–horseradish peroxidase was added to the wells, and the 
plates were allowed to incubate at room temperature again for 1 h. Thereafter, the plates 
were washed six times with Tween/PBS and finally developed with a chemoluminescence 
ELISA reagent (Boehringer Mannheim, Mannheim, Germany) according to the 
manufacturer’s instructions. All serum samples were measured at 1:25 dilution. Each 
sample was measured in triplicate, and the anti–VAP-1 value was calculated by subtracting 
the mean background value of the negative control from the mean value of VAP-1 23.  
Each assay included a titration of the quantified tonsil lysate; this titration was used to 
generate a standard curve. To obtain a protein milieu similar to the serum samples, tonsil 
lysate standards were diluted in blocking solution that contained as much VAP-1–depleted 
human serum as the test samples contained patient serum. Calculations of the amount of 
sVAP-1 in the serum samples were made by comparing the specific VAP-1 values with a 
standard curve of titrated tonsil lysate using a linear regression analysis 23.  
The adhesive function of VAP-1 is important in optimal oligosaccharide modifications since 
desialylated VAP-1 does not bind to lymphocytes 30. The lymphocyte ligand of VAP-1 is 
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unknown whereas the enzymatic reaction takes place independently within the rotund 
buried catalytic center of the molecule 31.   
VAP-1 is postulated as a mediator of adhesion of effector lymphocytes to tumor vasculature. 
It is an endothelial adhesion molecule that is up-regulated at inflammation sites and 
mediates lymphocyte binding to inflamed endothelium 23.   
Similar to the membrane-bound endothelial VAP-1 1, circulating VAP-1 involves effusive 
sialic acid decorations (moieties). The finding of effusive sialic acid remnants in VAP-1 is 
especially noteworthy because the adhesive function of VAP-1 depends on its sialic acids 1. 
VAP-1 is a deeply sialylated molecule that might be functionally active.   
The probable biological effects of VAP-1 could affect the expression or function of other 
adhesion molecules in vivo or in vitro in primary endothelial cells and in liver endothelial 
cells. These effects of VAP-1 on the synthesis of other adhesion molecules such as 
fucosyltransferases or sulfotransferases might contribute to the significantly rising capability 
of VAP-1 transfectants to effect lymphocyte accession.  
VAP-1 mediates the leukocyte subtype-specific recognition of HEVs under nonstatic 
conditions in humans, and hence, it represents a previously unknown method of achieving 
selectivity of the leukocyte-endothelial interactions in the multistep adhesion cascade. VAP-
1 is able to mediate the adhesion of PLN and HEV. Moreover, VAP-1 extends the role of 
carbohydrate-dependent lymphocyte–endothelial cell interactions 20.  
VAP-1 mediates HEV binding of lymphocytes but not of monocytes. Adhesion of T and B 
cells was independent of VAP-1. VAP-1 mediated oligosaccharide-dependent adhesion to 
endothelial cells under non-static harvest conditions 20, implying that it is involved in the 
adhesion cascade. 
Hepatic endothelial cells are lined by specialized endothelium that supports lymphocyte 
adhesion and recruitment in an optimal low-shear environment 31. Hepatic endothelium has 
a phenotype that is different from the endothelium of other vascular beds. In vivo hepatic 
endothelial cells express low levels of CD31 which are the most expansive entrapment 
receptors in other tissues 32. Human hepatic endothelial cells secrete the endothelial 
adhesion molecule VAP-1 33, which is major defective from non-inflamed vessels in 
extralymphoid organs 34. The ability of VAP-1 to mediate sialic acid-dependent adhesion 
suggests that it could have a particular function in the liver by mediating shear-dependent 
adhesion in the selectins 15. However, human liver endothelial cell behavior under 
conditions of shear stress is unknown. 
VAP-1 on liver endothelium promotes lymphocyte adhesion under laminar shear stress but 
not in hepatic roaming in vivo 35; VAP-1 is a mediator of lymphocyte transendothelial 
migration, but the capability of VAP-1 to promote adhesion and transendothelial migration 
is blocked by specific inhibitors of its enzyme activity 35. Functional characterization of VAP-
1 has not been conducted because the molecule is not expressed on the cell surface of human 
endothelial cell lines 22.  
In some studies, rising levels of serum VAP-1 were found in patients with hepatocellular 
cancer 36, 37. These results suggest that increasing levels of VAP-1 contribute to the elevated 
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adhesion of lymphocytes to vascular endothelial cells on the periphery of primary liver 
tumors. This mechanism could increase the immune response at the tumor where other 
adhesion molecules involved in the multistep adhesion cascade are also elevated in primary 
liver tumors. The rise in VAP-1 expression is specific to liver tumors because other non-
hepatic tumors are not associated with elevated levels of VAP-1. 
VAP-1 expression occurs in the hepatic vascular bed 38, 39. This occurrence suggests that 
some of the elements of the adhesion cascade in the hepatic vascular bed differ from those in 
post capillary venules.  
VAP-1 mediated adhesion is consistent with the finding of VAP-1–dependent lymphocyte 
adhesion to rat peripheral lymph node endothelial cells transfected with human VAP-1 
and with recent intravital studies where it has been shown to act as a brake for 
neutrophils in rabbit mesenteric blood vessels 39. The precise nature of the adhesion 
mediated by VAP-1 was unclear, although the total number of adherent cells was reduced 
with the inhibition of VAP-1, suggesting that its receptor is active at different points in the 
adhesion cascade. 
The inhibition of adhesion by blockade of VAP-1 had a marked inhibitory effect on 
lymphocyte transendothelial migration that was independent of its capability to assist 
adhesion. This effect was specific for VAP-1. It has also been proposed that VAP-1 mediates 
the transmigration of adherent leukocytes 28.  
VAP-1 is a monoamine oxidase, and this functionality was demonstrated with soluble VAP-
1 protein 40. Recent reports suggest that the adhesive and enzymatic functions of VAP-1 are 
closely linked. Some specific inhibitors block the enzymatic activity of VAP-1, and the 
specific semicarbazide-sensitive amine oxidase inhibitor (SSAO), semicarbazide, and a 
broad-acting monoamine oxidase inhibitor, hydroxylamine, both decreased lymphocyte 
adhesion and transmigration. The enzymatic activity of VAP-1 is thought to be important in 
the adhesion of lymphocytes to VAP-1–transfected cells. 
This effect was specific for hepatic endothelial cells that express VAP-1 since adhesion and 
transmigration of lymphocytes was observed.  Other molecules have been shown to share 
adhesive and enzymatic properties, but VAP-1 is the only adhesion molecule with amino 
oxidase activity 23, 40. The active site of the SSAO in VAP-1 may mediate adhesion via 
interactions with immobilized amine residues on the lymphocyte surfaces 40. The fact that 
the inhibitors had a similar effect on transendothelial migration is the first demonstration of 
enzymatic regulation of this process. 
The identification of VAP-1 as a new contact-initiating ligand suggests that it may be part of 
an optimal molecular pathway for regulating the specificity and multiplicity of the initial 
steps of lymphocyte–endothelial cell interactions. 
VAP-1 may be a molecule that is template expressed in the liver tumor vasculature but 
down-regulated in some tumors during the growth of the malignancy or not up-regulated in 
some other tumors. Since VAP-1 clearly binds to the blood vessels of liver tumors, it is 
conceivable that the up-regulation of VAP-1 in liver tumors with a low level of VAP-1 
expression may improve the treatment of hepatocellular carcinoma 20, 40, 41.   
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